BRAF and cancer: Compared to some cancers with recurrent point mutations conferring sensitivity to drugs, such as the BRAF V600E mutation conferring sensitivity to BRAF/MEK inhibition in melanoma, the LMS genome is charactered by low TMB and rare actionable alterations to confer meaningful clinical benefit derived from a targeted therapy.